Vincent Rajkumar on the High Price of Cancer Drugs

Episode Summary

Executive Summary: Russ Roberts and Vincent Rajkumar examine why cancer drugs—using multiple myeloma as the case study—cost so much and what could be done. Rajkumar argues prices are driven by R&D costs, patent-based monopoly power, patient desperation, physician incentives, and a U.S. system that lets drug prices rise without value-based negotiation.

Main Topics: Multiple myeloma and modern treatment (Priority: 5/5): Rajkumar explains what multiple myeloma is, how it affects patients, and the current treatment pathway: combination chemotherapy, stem cell transplant for eligible patients, then long-term maintenance therapy. Why cancer drugs are so expensive (Priority: 5/5): The discussion identifies several drivers of high prices: expensive clinical trials, patent and regulatory exclusivity, limited competition, vulnerable patients willing to pay, and physician reimbursement incentives. Monopoly power and drug sequencing (Priority: 5/5): Even when multiple drugs exist, each is often effectively a monopoly during its patent life and is used in sequence or combination, limiting competitive pressure on price. Medicare, insurance, and distorted incentives (Priority: 5/5): Because insurers and Medicare often pay the bill, patients are insulated from prices, while Medicare cannot negotiate Part D drug prices, allowing manufacturers to set very high prices. Value-based pricing and European-style negotiation (Priority: 4/5): Rajkumar proposes tying reimbursement to quality-adjusted life years and allowing a negotiation process that prices drugs based on value rather than simply FDA approval. Generic competition, re-importation, and market entry (Priority: 4/5): He advocates easier generic entry, reduced legal tactics that delay competition, and allowing personal re-importation from lower-price countries. Innovation and whether high prices are necessary (Priority: 4/5): Roberts and Rajkumar debate whether high prices are needed to spur innovation; Rajkumar argues excessive prices may actually reduce innovation by encouraging 'me-too' drugs and incremental modifications.

Key Arguments: Multiple myeloma is a serious, often relapsing blood cancer, but treatment advances have roughly doubled survival, making access to effective drugs enormously valuable. Cancer drug pricing is not a normal market outcome because the buyer is often Medicare or an insurer, not the individual patient, so price sensitivity is weak. Patent protection and the sequential nature of cancer treatment create effective monopolies: a given drug can face no true substitute when a patient reaches that stage of therapy. Doctors can be nudged toward more expensive treatments by reimbursement rules, especially when they administer and profit from chemotherapy in their own offices. Patients facing life-threatening illness are unusually willing to pay for small benefits, which weakens price discipline and makes exploitation easier. The FDA focuses on safety and efficacy, not value; without a second-stage value assessment, drugs can enter the market at very high prices regardless of how much benefit they add. Value-based pricing would compare a drug’s benefit and side effects using quality-adjusted life years, allowing better alignment between price and therapeutic value. Generic entry and re-importation could create more competition and lower prices, but would require legal and regulatory changes. High prices may not maximize innovation; when firms can make high profits from minor modifications, they may prefer 'me-too' products over risky breakthrough research.

Data Points: Annual U.S. multiple myeloma cases: 25,000 to 30,000 - Estimated number of Americans diagnosed each year Survival before newer drugs: 3 to 4 years - Typical lifespan for myeloma patients before Velcade and Revlimid Survival after newer drugs: 7 to 10 years or longer - Improved survival with modern therapies Age group most affected: Over 65 - Multiple myeloma is described as primarily a disease of elderly patients Younger incidence: 4% to 5% under age 40 - Share of patients diagnosed before age 40 Initial chemotherapy duration: About 4 months - First-line treatment for transplant-eligible patients Transplant process duration: About 2 months - Time added by autologous stem cell transplantation Maintenance therapy length: 3 to 4 years - Typical duration of Revlimid maintenance until the disease becomes refractory Revlimid cost: About $15,000 per month - Maintenance pill price cited for Revlimid Velcade cost: About $5,000 per month - Monthly cost cited during initial treatment Cancer drug price threshold: More than $100,000 per year - Rajkumar says essentially all new cancer drugs in recent years are priced at or above this level Drug development cost estimate: $750 million to several billion dollars - Estimated cost range to bring a new drug to market Patent/exclusivity window: 7 to 10 years - Period during which a drug can effectively hold monopoly protection Medicare reimbursement formula: Average sales price plus 6% - How office-administered chemotherapy is reimbursed under Medicare Part B Daraprim price increase example: From $1.50 to about $750 - Used to illustrate how monopoly pricing can work in pharmaceuticals Quality-adjusted life year benchmark: Up to about 3x GDP per capita - Common benchmark cited for willingness to reimburse one year of perfect-quality life New drug benefit example: One year of life at zero side effects = 1 QALY - Illustrates how value-based pricing would work European price reference: About $70,000 to $80,000 per QALY - Example of typical European willingness-to-pay range mentioned

Pivotal Quotes: "The alternative is death." — Russ Roberts: He frames the urgency and life-or-death stakes of cancer-drug pricing "We don't understand the human body like a car mechanic understands the car." — Vincent Rajkumar: Closing reflection on why medicine requires probabilistic testing and why cancer is hard to cure "The curious task of economics is to demonstrate to men how little they really know about what they imagine they can design." — Russ Roberts: Final comparison linking Hayek’s insight to medicine and public policy

Implications: Listeners should see cancer-drug prices as a policy design problem, not just corporate greed. Reform likely requires Medicare negotiation, value-based pricing, faster generic entry, and fewer incentives for costly overuse.